Mayne Pharma Group Ltd (MYX) — Capital Reinvestment Ratio
Latest as of June 2025:
0.17x
Mayne Pharma Group Ltd (MYX) has a Capital Reinvestment Ratio of 0.17x as of June 2025, meaning it reinvests 0% of its operating cash flow (AU$31.98 Million) in capital expenditures (AU$5.40 Million). See MYX cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.17x
Capex / Operating Cash Flow
Operating Cash Flow
AU$31.98 Million
AUD
Capital Expenditures
AU$5.40 Million
AUD
Data as of
Jun 2025
Most recent filing
Mayne Pharma Group Ltd Capital Reinvestment Ratio (2010–2025)
This chart tracks Mayne Pharma Group Ltd's Capital Reinvestment Ratio across 12 annual periods.
Annual Capital Reinvestment Ratio for Mayne Pharma Group Ltd (2010–2025)
Year-by-year Capital Reinvestment Ratio for Mayne Pharma Group Ltd from 2010 to 2025. For live market cap and broader valuation context, see Mayne Pharma Group Ltd stock valuation.
| Year | Reinvestment Ratio | Operating CF (AUD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.70x | AU$17.47 Million | AU$12.28 Million | ▲ +32.3% |
| 2021 | 0.53x | AU$47.26 Million | AU$25.10 Million | ▲ +12.5% |
| 2020 | 0.47x | AU$99.78 Million | AU$47.12 Million | ▲ +322.6% |
| 2019 | 0.11x | AU$106.61 Million | AU$11.91 Million | ▼ -74.9% |
| 2018 | 0.45x | AU$121.50 Million | AU$54.18 Million | ▼ -19.4% |
| 2016 | 0.55x | AU$53.50 Million | AU$29.59 Million | ▲ +197.1% |
| 2015 | 0.19x | AU$22.42 Million | AU$4.17 Million | ▲ +15.8% |
| 2014 | 0.16x | AU$26.14 Million | AU$4.20 Million | ▼ -94.8% |
| 2013 | 3.08x | AU$6.84 Million | AU$21.06 Million | ▲ +1517.0% |
| 2012 | 0.19x | AU$13.39 Million | AU$2.55 Million | ▼ -63.1% |
| 2011 | 0.51x | AU$4.09 Million | AU$2.10 Million | ▲ +1225.0% |
| 2010 | 0.04x | AU$10.26 Million | AU$398.56K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow